Volume 23 - Special issue
mjms 2021, 23 - Special issue: 51-56 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaei M, Handali S. Therapeutic monoclonal antibodies at phase 3 clinical study for management of Covid-19. mjms 2021; 23 :51-56
URL: http://mjms.modares.ac.ir/article-30-45415-en.html
URL: http://mjms.modares.ac.ir/article-30-45415-en.html
1- Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran , rezaei.mohsen@gmail.com
2- Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
2- Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
Abstract: (2571 Views)
The new coronavirus was firstly identified in the late December 2019 that causes severe respiratory and other organ complications in Covid-19 patients. Although many attempts have been employed to introduce and provide effective medications against this infection, there is still no definitive treatment for the infection. However some agents have shown promising effects in patients and some others are in preliminary or clinical studies. Monoclonal antibodies are of great interest in the treatment of Covid-19, but despite the fact that more than 120 clinical trials have been performed or are being completed; only tocilizumab has shown promising results and is sometimes used in therapeutic protocols. In this review, therapeutic monoclonal antibodies against Covid-19 that are currently in phase 3 or higher clinical trial have been discussed.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |